Wayfinding Financial LLC Has $1.32 Million Stock Holdings in AbbVie Inc. (NYSE:ABBV)

Wayfinding Financial LLC decreased its position in shares of AbbVie Inc. (NYSE:ABBV) by 0.8% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,286 shares of the company’s stock after selling 53 shares during the quarter. Wayfinding Financial LLC’s holdings in AbbVie were worth $1,317,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Brighton Jones LLC lifted its stake in shares of AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after purchasing an additional 3,401 shares during the period. Revolve Wealth Partners LLC lifted its stake in shares of AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after purchasing an additional 3,064 shares during the period. Proficio Capital Partners LLC lifted its stake in shares of AbbVie by 50.8% in the 4th quarter. Proficio Capital Partners LLC now owns 6,622 shares of the company’s stock valued at $1,177,000 after purchasing an additional 2,230 shares during the period. Promus Capital LLC acquired a new position in shares of AbbVie in the 4th quarter valued at $30,000. Finally, Vestmark Advisory Solutions Inc. lifted its stake in shares of AbbVie by 13.5% in the 4th quarter. Vestmark Advisory Solutions Inc. now owns 21,100 shares of the company’s stock valued at $3,750,000 after purchasing an additional 2,505 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on ABBV shares. Bank of America increased their price target on AbbVie to $204.00 and gave the company a “hold” rating in a research note on Monday, June 9th. BNP Paribas upgraded shares of AbbVie to a “hold” rating in a research report on Thursday, May 8th. Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 22nd. Erste Group Bank upgraded shares of AbbVie to a “strong-buy” rating in a research report on Monday, March 17th. Finally, Evercore ISI upped their price objective on shares of AbbVie from $204.00 to $205.00 and gave the company an “outperform” rating in a research report on Monday, April 28th. Eight analysts have rated the stock with a hold rating, seventeen have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and a consensus price target of $211.29.

AbbVie Trading Down 0.7%

Shares of ABBV stock opened at $189.50 on Friday. The firm has a 50 day moving average price of $187.37 and a two-hundred day moving average price of $188.46. The company has a quick ratio of 0.64, a current ratio of 0.76 and a debt-to-equity ratio of 44.14. The company has a market capitalization of $334.73 billion, a PE ratio of 80.64, a price-to-earnings-growth ratio of 1.26 and a beta of 0.48. AbbVie Inc. has a 12-month low of $163.63 and a 12-month high of $218.66.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.40 by $0.06. The firm had revenue of $13.34 billion during the quarter, compared to the consensus estimate of $12.91 billion. AbbVie had a net margin of 7.31% and a return on equity of 412.03%. The business’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period last year, the business posted $2.31 earnings per share. As a group, analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th will be issued a dividend of $1.64 per share. The ex-dividend date of this dividend is Tuesday, July 15th. This represents a $6.56 annualized dividend and a dividend yield of 3.46%. AbbVie’s dividend payout ratio is presently 279.15%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.